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Linear regressionmodel testing the association between laboratory data (categorized) and
number of chronic diseases.
Number of Chronic Disease Coef. P N z [95% Conf.Interval]
Cyst C 0.926 0.044 0.025 1.828
Lp(a) 1.529 0.001 0.625 2.432
CRP 0.961 0.038 0.052 1.870
Sex −0.726 0.071 −1.514 0.063
Age −0.002 0.945 −0.062 0.058C-reactive protein, lipoprotein (a) and cystatin C levels increasewith
multimorbidity in older persons
Dear Editor
Multimorbidity, the co-existence of chronic diseases within the
same individual has been associated with a low-grade pro inﬂamma-
tory status and different epidemiological and clinical studies have
found that the “low-grade chronic proinﬂammatory state” typical
of older persons [1,2] is characterized by high levels of serum
cytokines, such as Interleukin-6 (IL-6) and Tumor Necrosis Factor
alpha (TNF-alpha), and acute phase proteins, such as C-reactive
protein (CRP), that are considered risk factors for several chronic
diseases [3] and predict a variety of adverse health outcome [4,5].
Thus, it is reasonable to hypothesize that older persons with chronic
inﬂammation are more likely to be affected by or to develop
multimorbidity.
In spite of this potential clinical utility, the above mentioned
markers, with the exception of CRP, are not available in the major-
ity of clinical laboratories since they are mainly used for research
purpose and few commercial diagnostic kit with standardized
protocols, well deﬁned range limits, quality internal and external
controls are available on the most used platform. Therefore, even
if they provide useful information, their application in the daily
clinical practice is difﬁcult and often expensive. For this reason
we investigated the relationship between inﬂammatory
biomarkers that can be easily measured and adopted by most
clinical laboratories with multimorbidity. In particular we investi-
gate the relationship of CRP, Lp(a), and Cyst-C levels with
multimorbidity in a sample of community-dwelling older collected
for the study ‘ANZIANI IN-RETE’, a prospective population-based
study already described by Bianchetti et all [6]. In this population
of 134 people we evaluate multimorbidity as the number of chronic
diseases within each participant. Commercially available assays
were used according to manufacturer's instruction to evaluate
serum Lp(a) (the latex lipoprotein reagent; Siemens Healthcare
Diagnostics), Cyst-C and CRP plasma levels (with immunoassay
techniques; Siemens). We used the biomarkers levels both as linear
variables and categorized according to the references valuesTable 1
Bi-variate analysis between thenumber of chronic pathologies, the socio-demographic variables
“·” indicates a p-value b 0.1.
Number of Chronic Disease 0/1 2/3 4
Age mean(SD) 73(1.2) 77.3(0.94) 78
Female sex, % 45.8 52.4 66
Education, median(IQR) 13(13–18) 13(8–18) 13
Inﬂammatory markers
CRP b5 mg/L, % 92.9 82.2 65
Lp(a) b0.3 g/L,% 85.7 86.4 60
Cyst C b 1.11 mg/L,% 91.7 61.5 43
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adopted by clinicians (Lp(a) N 0,3 g/L, Cyst-C value N1.11 mg/L
and CRP N 5 mg/L).
Variables were summarized as mean ± standard deviation for
continuous variables and frequencies for discrete variables. The
Chi-square statistic, Goodman and Kruskal's gamma and Spearman's
Rho were used to study bi-variate associations between the socio-
demographic variables, the inﬂammatory markers and the number
of chronic diseases. To determine factors independently correlated
with the number of chronic pathologies multivariate analysis were
carried out by multiple linear regression models. All p-values b 0.05
were considered to be statistically signiﬁcant.
Population enrolled for the study included 134 participants, the
mean age was 77.7 (SD 7.6); 59.3% were women Mean value of
Lp(a) was 0,2 g/L (SD 0.32), 4,69 mg/L (SD 0,32) and 1.11 mg/L (SD
0,47) for CRP and Cyst C respectively . Sociodemographic and labora-
tory data according to being affected by 0/1, 2–3 or N4 chronic dis-
eases are showed in Table 1. Increasing age, female sex and lower
education were signiﬁcantly associated with higher number of
diseases.
The majority of persons in the group of those with zero or 1 disease
had normal levels of the markers, as the number of chronic diseases in-
creased the percentage of person with normal value of the markers
decreased.
We also run two multivariate linear regression models to test the
association between the three biomarkers and multimorbidity
(number of diseases). The ﬁrst model include CRP, Lp(a) and Cyst-C
categorized according to previously deﬁned cut-off points. Higher
levels of all the three markers were associated with higher numberand the bio-markers variables. ** indicates a p-valueb 0.01, * indicates a p-value b 0.05 and
or more Test P-value
.9(0.73) Spearman's Rho = 0.24 0.0005**
.1 Goodman and Kruskal's gamma =−0.29 0.07·
(8–13) Spearman's Rho =−0.20 0.007**
.3 Goodman and Kruskal's gamma = 0.49 0.03*
.3 Goodman and Kruskal's gamma = 0.56 0.005**




Linear regressionmodel testing the association between laboratory data (continuous) and
number of chronic diseases.
Number of chronic pathologies Coef. P N z [95% Conf. Interval]
Cyst C 1.467 0.021 0.220 2.714
Lp(a) 1.771 0.005 0.522 3.020
PCR 0.002 0.930 −0.052 0.057
Sex −0.906 0.033 −1.737 −0.074
Age 0.003 0.927 −0.062 0.068
2 Letter to the Editorof diseases after adjusting for age and sex (Table 2). The second
model was run including CRP, Lp(a) and Cyst-C as continuous vari-
ables. Results from this model showed that Lp(a) and Cyst-C, but
not CRP were still signiﬁcantly associated with increasing number
of diseases (Table 3).
Our data showed that higher value of all the three biomarkers
correlated with an increase in the number of chronic conditions,
both when dichotomized as “high” versus normal and as continu-
ous variables. Among the three of them, CRP present some limita-
tion in evaluating multimorbidity since levels of CRP rise
signiﬁcantly during acute inﬂammation making evaluation of
multimorbidities more difﬁcult, and furthermore positive values
of this marker, even if correlate with multimorbidities, do not cor-
relate with the number of chronic disease that affect the individual.
Therefore, Lp(a) and Cyst-C could be more intriguing candidates for
monitoring multimorbidity.
Elevated plasma Lp(a) levels have been reported to be an indepen-
dent risk factor for coronary heart disease and stroke, but, to the best
of our knowledge, there are very few example that studied a possible
role for Lp(a) in the aging process or multimorbidity [7]. While Cyst-C
has been studied as a marker of renal function, other studies have
highlighted the potential role of Cyst-C as amarker of more general sys-
temic inﬂammation [8,9].
Very interestingly the above mentioned markers are indepen-
dently associated suggesting the possibility that they could be
used independently to monitor different type of morbidity even
if, unfortunately, we were not able to evaluate this issues in the
present study since our sample was too small. Furthermore differ-
ently from the most studied markers of inﬂammation, we propose
the use of diagnostic assay already available in most of clinical lab-
oratories. Standardized protocols, well deﬁned range limits, quality
internal and external controls and low costs compared to research
assay make them more interesting for monitoring inﬂammation
and related health conditions in older person.
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